RPGR and choroideremia: The preclinical and clinical trials are flourishing though, the complexity and challenges of retinal gene therapy have become clear this past year with pivotal clinical trials for RPGR (X-linked retinitis pigmentosa GTPase regulator), retinitis pigmentosa (NCT03116113), and choroideremia (NCT03496012) failing to meet their respective primary endpoints.